FEB 22, 2018 6:00 AM PST

Developing Personalized Cancer Neoantigen Vaccines

Presented at: Drug Discovery 2018
Speaker
  • Chief Scientific Officer, Vaccibody AS
    Biography
      Agnete B. Fredriksen is Co-Founder and joined Vaccibody in 2007. She holds a MSc, PhD from Institute of Immunology, Rikshospitalet Medical Center in Oslo where she designed and developed the first Vaccibody vaccine molecules. She received the King's Gold Medal for her PhD thesis describing Vaccibodies. Her focus is on cancer vaccines from idea to clinical development. Previous employment includes Affitech AS and Medinnova AS. Agnete is author on numerous scientific papers in the field of immunology, immunotherapy and vaccines. Inventor on several patents in the field of immunotherapy. She is board member for the BIA programme of NRC stimulating research in the Norwegian industry.

    Abstract

    Vaccibody has developed a unique platform technology able to substantially potentiate vaccines by an inherent mechanism that attract, activate and deliver antigens to antigen presenting cells. Currently, Vaccibody is heavily focusing on using the platform technology to generate unique individualized cancer neoantigen vaccines. Recent clinical data indicate an important role of T cell immunity to cancer neoantigens in patients that benefit from immunotherapies. A cancer neoantigen vaccine should be customized for each individual patients cancer-specific somatic mutations and hence warrant manufacturing of one vaccine per patient. By using the DNA vaccine format encoding for the Vaccibody protein, a rapid, cost-effective and robust manufacturing process has been generated which lends itself perfectly to develop commercially viable patient-specific vaccines on demand. Supportive preclinical data with neoantigen based DNA vaccines as well as clinical data with a similar Vaccibody DNA vaccine using viral antigens support a favourable safety, tolerability and efficacy profile. A clinical study using targeted Vaccibody neoepitope DNA vaccines in multiple advanced cancer indications is planned to start Q1 2018.


    Show Resources
    You May Also Like
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    MAY 08, 2020 10:00 AM PDT
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    MAR 24, 2020 10:00 AM PDT
    C.E. CREDITS
    MAR 24, 2020 10:00 AM PDT
    DATE: March 24, 2020 TIME: 10:00 am PDT, 1:00pm EDT The Clampfit software module is a useful tool to manipulate and analyze electrophysiological data acquired by pCLAMP™ software. Rece...
    MAR 31, 2020 7:00 AM PDT
    C.E. CREDITS
    MAR 31, 2020 7:00 AM PDT
    DATE: March 31, 2020 TIME: 7:00am PT, 10:00am PT Please join us for this webinar, during which we will present and discuss the promotion of NK cell-driven tumor immunity. In addition, we wil...
    APR 16, 2020 9:00 AM PDT
    C.E. CREDITS
    APR 16, 2020 9:00 AM PDT
    DATE: April 16, 2020 TIME: 9:00am PT, 12:00pm ET There is an increasing need to evaluate and understand unique phenotypes and mechanisms of action within the tumor microenvironment. Existing...
    JUN 23, 2020 10:00 AM PDT
    C.E. CREDITS
    JUN 23, 2020 10:00 AM PDT
    DATE: June 23, 2020 TIME: 10:00am PT Human mesenchymal stromal or stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach for many diseases, s...
    Loading Comments...
    Show Resources
    Attendees
    • See more